Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076753712> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2076753712 endingPage "424" @default.
- W2076753712 startingPage "418" @default.
- W2076753712 abstract "Botulinum toxin type B (BTX-B, Myobloc, San Francisco, CA, USA) was FDA-approved for the treatment of cervical dystonia in December 2000. It has since been used off-label for the treatment of axillary hyperhidrosis. However, there are sparse data in the medical literature evaluating the safety and efficacy of Myobloc (botulinum toxin type B) for this indication.To assess the safety, efficacy and duration of action of Myobloc (botulinum toxin type B) in the treatment of bilateral axillary hyperhidrosis.This study was a double-blinded, randomized, pilot study conducted in an outpatient office setting at a private academic medical center beginning in November 2001. Twenty-three male and female volunteers between the ages of 18 and 80 were screened for participation; 20 participants with primary axillary hyperhidrosis were enrolled. Participants were injected subcutaneously with either Myobloc (botulinum toxin type B) (2500 U, or 0.5 ml, per axilla) or 0.5 ml vehicle (100 mM NaCl, 10 mM succinate, and 0.5 mg/ml human albumin) into bilateral axillae. Participants who received placebo were rolled over and received Myobloc (botulinum toxin type B) at subsequent visits. All participants were followed until sweating returned to baseline levels. This trial was initially conceived as a placebo-controlled study; however, owing to the insufficient size of the placebo group, the placebo arm of this trial was dropped during data analysis. The main outcome measures were safety, efficacy, and duration of effect.According to participant assessment of axillary hyperhidrosis improvement (A-HI) and quality of life (A-HQOL) scores and the physician assessment scores, a significant difference was observed in treatment response at Day 30 in the participants receiving Myobloc (botulinum toxin type B) injections. Duration of action ranged from 2.2 to 8.1 months (mean 5.0 months). The adverse event profile included bruising, flu-like symptoms, and dry eyes.Myobloc (botulinum toxin type B) proved to be safe and efficacious for the treatment of bilateral axillary hyperhidrosis. More studies are needed to assess the duration of response using different doses of Myobloc (botulinum toxin type B)." @default.
- W2076753712 created "2016-06-24" @default.
- W2076753712 creator A5015727369 @default.
- W2076753712 creator A5029564827 @default.
- W2076753712 creator A5039274047 @default.
- W2076753712 creator A5042119836 @default.
- W2076753712 creator A5055009275 @default.
- W2076753712 creator A5066435637 @default.
- W2076753712 creator A5079150626 @default.
- W2076753712 date "2005-05-01" @default.
- W2076753712 modified "2023-10-10" @default.
- W2076753712 title "Pilot study of the safety and efficacy of Myobloctm (botulinum toxin type B) for treatment of axillary hyperhidrosis" @default.
- W2076753712 cites W1973956716 @default.
- W2076753712 cites W1975741186 @default.
- W2076753712 cites W1982019854 @default.
- W2076753712 cites W2002048052 @default.
- W2076753712 cites W2007944911 @default.
- W2076753712 cites W2009200901 @default.
- W2076753712 cites W2020187066 @default.
- W2076753712 cites W2028647180 @default.
- W2076753712 cites W2044095951 @default.
- W2076753712 cites W2050345355 @default.
- W2076753712 cites W2109945552 @default.
- W2076753712 cites W4252167954 @default.
- W2076753712 doi "https://doi.org/10.1111/j.1365-4632.2004.02531.x" @default.
- W2076753712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15869543" @default.
- W2076753712 hasPublicationYear "2005" @default.
- W2076753712 type Work @default.
- W2076753712 sameAs 2076753712 @default.
- W2076753712 citedByCount "37" @default.
- W2076753712 countsByYear W20767537122012 @default.
- W2076753712 countsByYear W20767537122013 @default.
- W2076753712 countsByYear W20767537122014 @default.
- W2076753712 countsByYear W20767537122015 @default.
- W2076753712 countsByYear W20767537122016 @default.
- W2076753712 countsByYear W20767537122017 @default.
- W2076753712 countsByYear W20767537122018 @default.
- W2076753712 countsByYear W20767537122019 @default.
- W2076753712 countsByYear W20767537122022 @default.
- W2076753712 countsByYear W20767537122023 @default.
- W2076753712 crossrefType "journal-article" @default.
- W2076753712 hasAuthorship W2076753712A5015727369 @default.
- W2076753712 hasAuthorship W2076753712A5029564827 @default.
- W2076753712 hasAuthorship W2076753712A5039274047 @default.
- W2076753712 hasAuthorship W2076753712A5042119836 @default.
- W2076753712 hasAuthorship W2076753712A5055009275 @default.
- W2076753712 hasAuthorship W2076753712A5066435637 @default.
- W2076753712 hasAuthorship W2076753712A5079150626 @default.
- W2076753712 hasConcept C121608353 @default.
- W2076753712 hasConcept C126322002 @default.
- W2076753712 hasConcept C141071460 @default.
- W2076753712 hasConcept C142724271 @default.
- W2076753712 hasConcept C168563851 @default.
- W2076753712 hasConcept C204787440 @default.
- W2076753712 hasConcept C27081682 @default.
- W2076753712 hasConcept C2776608951 @default.
- W2076753712 hasConcept C2777478456 @default.
- W2076753712 hasConcept C2778650131 @default.
- W2076753712 hasConcept C42219234 @default.
- W2076753712 hasConcept C530470458 @default.
- W2076753712 hasConcept C71924100 @default.
- W2076753712 hasConceptScore W2076753712C121608353 @default.
- W2076753712 hasConceptScore W2076753712C126322002 @default.
- W2076753712 hasConceptScore W2076753712C141071460 @default.
- W2076753712 hasConceptScore W2076753712C142724271 @default.
- W2076753712 hasConceptScore W2076753712C168563851 @default.
- W2076753712 hasConceptScore W2076753712C204787440 @default.
- W2076753712 hasConceptScore W2076753712C27081682 @default.
- W2076753712 hasConceptScore W2076753712C2776608951 @default.
- W2076753712 hasConceptScore W2076753712C2777478456 @default.
- W2076753712 hasConceptScore W2076753712C2778650131 @default.
- W2076753712 hasConceptScore W2076753712C42219234 @default.
- W2076753712 hasConceptScore W2076753712C530470458 @default.
- W2076753712 hasConceptScore W2076753712C71924100 @default.
- W2076753712 hasIssue "5" @default.
- W2076753712 hasLocation W20767537121 @default.
- W2076753712 hasLocation W20767537122 @default.
- W2076753712 hasOpenAccess W2076753712 @default.
- W2076753712 hasPrimaryLocation W20767537121 @default.
- W2076753712 hasRelatedWork W2051374626 @default.
- W2076753712 hasRelatedWork W2057498645 @default.
- W2076753712 hasRelatedWork W2058529093 @default.
- W2076753712 hasRelatedWork W2067414253 @default.
- W2076753712 hasRelatedWork W2122926839 @default.
- W2076753712 hasRelatedWork W2138934242 @default.
- W2076753712 hasRelatedWork W2171771133 @default.
- W2076753712 hasRelatedWork W2615422280 @default.
- W2076753712 hasRelatedWork W2991758096 @default.
- W2076753712 hasRelatedWork W59248287 @default.
- W2076753712 hasVolume "44" @default.
- W2076753712 isParatext "false" @default.
- W2076753712 isRetracted "false" @default.
- W2076753712 magId "2076753712" @default.
- W2076753712 workType "article" @default.